株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

有毛細胞白血病の世界市場:治療法、地理別の成長率、動向および予測

Hairy Cell Leukemia Market - Growth, Trends, and Forecast (2020 - 2025)

発行 Mordor Intelligence LLP 商品コード 660532
出版日 ページ情報 英文 120 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.69円で換算しております。
有毛細胞白血病の世界市場:治療法、地理別の成長率、動向および予測 Hairy Cell Leukemia Market - Growth, Trends, and Forecast (2020 - 2025)
出版日: 2020年02月01日 ページ情報: 英文 120 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

有毛細胞白血病市場は、2018年から2023年の予測期間中に、5%のCAGRで成長する見通しです。有毛細胞白血病は、異常なリンパ球の蓄積に関連する血液がんの一種です。

当レポートでは、世界の有毛細胞白血病市場を調査し、全体的な市場動向、製品・地域別の詳細動向、市場成長への影響要因の分析、競合情勢、主要企業のプロファイルなどを包括的にまとめています。

目次

第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 市場の概要

  • 現在の市場シナリオ
  • ポーターのファイブフォース分析
    • サプライヤーの交渉力
    • 消費者の交渉力
    • 新規参入の脅威
    • 代替製品とサービスの脅威
    • 業界内での競争

第6章 成長要因、阻害要因、機会、課題の分析(DROC)

  • 市場の成長要因
    • 診断率の上昇
    • 高齢者人口の増加
  • 市場の阻害要因
    • 重要でない調査研究のために症状に対する認識が欠如
    • 地方病院における限られた保健サービス
  • 市場機会
  • 主な課題

第7章 市場セグメンテーション

  • 治療法別
    • 化学療法
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第8章 競合情勢

  • M&A分析
  • 合意、コラボレーション、パートナーシップ
  • 新製品の発売

第9章 主要企業

  • AbbVie
  • Astellas Pharma
  • AstraZeneca
  • Biogenomics Limited
  • F. Hoffmann-La Roche AG
  • Incyte Corp.
  • Juno Therapeutics
  • MedImmune
  • Novartis
  • その他

第10章 市場の将来展望

目次
Product Code: 46197

Hairy cell leukemia is a very rare type of cancer, which accounts for approximately 2%, out of all the leukemia's. Hairy cell leukemia is characterized by the uncontrolled accumulation of lymphocytes by bone marrow. According to National Organization for Rare Disorders, approximately 600-800 new cases are diagnosed each year in the United States. Most of the affected individuals are males 50 years of age or older. Early diagnosis can help the patients live longer. In recent years, there are advanced diagnostic tests to detect the hairy cell leukemia. First and foremost diagnostic test is a complete blood profile which clearly indicates the total number of lymphocytes, which indicates the disease. Physicians can easily diagnose, if there is an enlarged spleen, by physical examination. One important confirmation test is presence of hairy cells in the blood in the lab tests. Most of the patients also require bone marrow biopsy for confirmation. Diagnosis rate of hairy cell leukaemia is increased during last two-three decades, which is expected to drives the market in the forecast period.

Key Market Trends

Chemotherapy Segment is Expected to Register a Significant Growth Over the Forecast Period

Based on therapy, it is segmented into chemotherapy and Targeted Therapy. The key factor contributing to the growth of the chemotherapy segment is the rising incidence of leukemia cases. According to the American Cancer Society estimates, there were around 22,840 death from leukemia in 2019. Many companies are focusing on developing breakthrough products for the treatment of hairy cell leukemia in order to maintain their competitive advantage and penetrate new regional markets. Chemotherapy drugs, specifically purine analogs such as cladribine and pentostatin, are considered as an initial treatment option for most individuals with hairy cell leukemia. Additionally, the increase in funding for companies involved in the research related to hairy cell leukemia is expected to boost the studied market.

North America holds the Largest Share in the Hairy Cell Leukemia Market

The hairy cell leukemia market holds the largest share in North America region due to the presence of high incidence rate, increase in geriatric population and advancements in the treatment of hairy cell leukaemia. According to National Organization for Rare Disorders, Hairy cell leukemia is a rare type of blood cancer, that affects about 6,000 persons in the United States. Europe and the Asia Pacific are followed next after North America owing to the presence of a diversified patient pool and emerging economies in these regions.

Competitive Landscape

The hairy cell leukemia market is competitive and many of the global players are into the market. For instance - Amgen Inc, AstraZeneca plc, BioGenomics Limited, F. Hoffmann-La Roche Ltd, Incyte Corp, Johnson & Johnson, Merck KGaA, Merck & Co, Inc. and Pfizer Inc. are providing these products across the globe.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Leukemia Cases
    • 4.2.2 Increase in Diagnosis Rates
    • 4.2.3 Growing Geriatric Population
  • 4.3 Market Restraints
    • 4.3.1 Lack of Awareness
    • 4.3.2 Limited Health Services in Rural Hospitals
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Therapy
    • 5.1.1 Chemotherapy
    • 5.1.2 Targeted Therapy
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Rest of the World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Amgen Inc.
    • 6.1.2 AstraZeneca plc
    • 6.1.3 BioGenomics Limited
    • 6.1.4 F. Hoffmann-La Roche Ltd
    • 6.1.5 Incyte Corp
    • 6.1.6 Johnson & Johnson
    • 6.1.7 Merck KGaA
    • 6.1.8 Merck & Co, Inc.
    • 6.1.9 Pfizer Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS